GEETA PATEL SPEAKS ABOUT HER EMOTIONAL JOURNEY AFTER A TERMINAL DIAGNOSIS
Geeta Patel had just got married and bought a house.
Then on August 25, 2020, the 25-year-old noticed a lump on her leg while having a bath and didn’t know what it was. The young estate agent from Wynyard was diagnosed with sarcoma, a cancer of the soft tissue, and despite treatment was told the disease had spread to her lungs and was deemed incurable.
Instead of giving up, she has bravely gone through gruelling radiotherapy, immunotherapy, and her current treatment of a clinical trial, where she takes chemotherapy in tablet form.
Two years later, and the 27-year-old is continuing to battle the deadly disease and supporting the Stand Up To Cancer campaign from Cancer Research UK. Eastern Eye spoke to Geeta about her deeply emotional journey, being told it was terminal, bravery, lifesaving clinical trial, future hopes, and key advice for those diagnosed with the disease.
What happened after you discovered the lump on your leg?
I didn’t think it was cancer. My husband Ankush is a dentist, and he wasn’t sure what it was. I started Googling and found something about sarcoma but didn’t think it could be that. I showed my work colleagues too. I then did a Zoom call with the GP and was referred for an ultrasound the next week. The GP rang a week afterwards and asked me to come in and bring someone.
How did you feel when that happened?
I called Ankush! He sounded worried and said that is what he says to people when he suspects mouth cancer. Suddenly, I was scared and started crying. I got to the doctor and rang the bell to go in, but due to Covid practices, I was waiting for Ankush. The receptionist gave me a bottle of water and I just sat there. My first question to the doctor was, “It’s not cancer is it?” and they said “we can’t rule it out”. I couldn’t breathe.
That must have been really harrowing. What happened next?
We asked about the next tests, and they said X-ray, biopsy, and MRI. There was a lump on one scan about 5cm and they said it was probably sarcoma. I was so upset and couldn’t believe it was what I had seen on Google that first day. I had to wait a week and it was the worst time of my life. They confirmed it and asked if I was fit and well, as they needed to check if it had spread. Then it clicked, I had a cough, which I thought might be because of aircon at work or something. But I just said, “it’s in my lungs”. I just knew. Every time it seemed the worst case was happening.
How did you feel when they confirmed the cancer had spread to your lungs?
We were both crying, and they said that chemotherapy had a 20 per cent chance of working. I had surgery on October 8, and started 30 sessions of radiotherapy in November, which continued until January 8. I was trying to be so positive. They said I was one of only a few people with this cancer type. I started immunotherapy in the hope it would shrink the tumours in my lungs. I asked if it was incurable and they said, yes. Ankush asked if that meant terminal too, and they said, yes. I can’t really remember that conversation too much as it was a blur.
On December 2021, you were told that the treatment wasn’t working at all. How did you get onto the clinical trial?
The tumour had grown in my lungs, and I was having trouble breathing. I was told about a trial at the Royal Marsden but doctors said that one of the tumours was near a main artery, so nothing could be done. They were talking about palliative care, and I was given morphine for pain.
How did you feel in that moment when they said nothing could be done?
Originally when I was diagnosed, I didn’t think I would die, but at that time it was so hard to be told they could not do anything more. I had to think about everything and was crying when I made a will. You don’t think about writing a will at 27 – there was so much to think about. That was in January.
How did you finally get onto the clinical trial?
I kept researching and spoke to a professor at the Royal Marsden who told me to come down, and I had an MRI. I was able to join the trial, which gives me chemotherapy in tablet form. There are side-effects. My feet and hands hurt. I can’t keep food down, but it has made a big difference.
The trial has made such a difference, and it’s amazing you are still with us. How is life now?
I have an MRI every six weeks. I go down to the Marsden and have scan in the morning, then results in the afternoon to check whether the cancer is still
responding to the treatment, so that I can keep going with it. Things are still hard. It’s hard to get around. I get breathless and can’t plan things in advance. It’s too scary.
What is the most difficult aspect of life for you now?
I had always wanted to have children and don’t know if that will ever be in my future. Everyone else I know seems to be having children or getting on with work. I am not working at the moment, as am not strong enough. It is hard seeing everyone else get on with things, like at work when they took new team photos without me in them.
Geeta with her husband Ankush
How much of a support has your wonderful husband Ankush been?
Ankush has been my rock. My diagnosis has changed our relationship, but it has made us learn more about each other. When I got the diagnosis, we were scared about losing each other, but he has been there for me the whole time. It has made us stronger.
What are your future hopes?
I’m lucky to be on this trial. It’s a phase three trial, so it’s hopefully going to be approved and keep my cancer at bay. My hope for the future is to live as long and healthily as I can. Even if it’s two or three years, I’ll be grateful. It would just give me hope and that’s what every cancer patient wants to hear; that they have hope for the future. To be told you have cancer, yes, it’s absolutely soul destroying, but then to be told ‘wait, there’s something we can do’. That’s music to someone’s ears.
Geeta in treatment
Tell us about the Cancer Research UK campaign Stand Up To Cancer that you are supporting?
The campaign is important. My experience has helped me appreciate how crucial research is and I’m determined to help more people survive. I hope by my story will encourage others to ‘stand up to cancer’ too and help to raise awareness and funds.
What key advice would you give those who have had a cancer diagnosis?
My advice is to live for every day. It has taught me to live in the moment and make memories when you can. I would say to people that some days are harder than others but don’t ever lose your willpower to keep going and always have hope.
Geeta Patel is supporting Stand Up To Cancer, a joint fundraising campaign from Cancer Research UK and Channel 4, bringing the UK together to accelerate life-saving cancer research.
Amazing progress has been made against cancer, but one in two people in UK will be diagnosed with it in their lifetime. To get involved and donate, visit SU2C.org.uk
Tourists stranded after Foça wildfire halts flights at Izmir airport
At least 550 people evacuated from homes in the region
Over 600 personnel deployed to contain the blaze
Strong winds and heat raise risk of further fires
Wildfires force airport shutdown in Turkish holiday hotspot
Hundreds of UK tourists, including several from Glasgow, have been left stranded after major wildfires swept through a popular holiday destination in western Turkey, forcing the closure of Izmir Adnan Menderes Airport.
The blaze broke out in the resort town of Foça, near Izmir, and was rapidly intensified by strong winds, prompting large-scale evacuations and flight disruptions. All operations at the airport were suspended from 4 pm local time due to ongoing extinguishing efforts, with multiple flights reportedly diverted.
More than 550 residents were evacuated from 175 homes in the Ilıpınar district, while emergency crews battled the fire for over 22 hours. The extensive response included 625 personnel, 46 fire engines, six helicopters, nine bulldozers and 13 water tankers.
Dramatic footage showed aircraft dropping water over the blaze in an effort to slow its spread. Authorities are still investigating the cause of the fire.
Süleyman Elban, Governor of Izmir Province, has urged residents and visitors to remain cautious, citing the combination of high temperatures and low humidity as factors that could lead to additional fires.
The Turkey wildfires have not been limited to Izmir. Blazes have also been reported this week in Kahramanmaraş, Bursa, Sakarya, Bilecik, Gaziantep, Bolu and Manisa, putting regional emergency services under sustained pressure.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Glutathione and anti ageing drugs under spotlight after Shefali Jariwala death
Shefali Jariwala died at 42 in Mumbai after reportedly collapsing post-fast; cause of death suspected to be cardiac arrest or blood pressure drop.
Police found anti-ageing pills, vitamin supplements, and glutathione injections at her residence.
Doctors stress the risks of unsupervised use of hormone-based and anti-ageing treatments.
Final post-mortem report expected in two days; no foul play suspected, case treated as accidental death.
The untimely death of actor-model Shefali Jariwala has sparked renewed concern over the unregulated use of anti-ageing treatments and self-medication. The 42-year-old, best known for her appearance in Kaanta Laga, was declared dead on arrival at a Mumbai hospital on Friday night. Initial investigations suggest she may have suffered a cardiac arrest following a steep drop in blood pressure, possibly linked to taking supplements on an empty stomach.
Shefali Jariwala death raises concern over anti ageing drugs and self medication Instagram/shefalijariwala
What caused Shefali Jariwala’s collapse? Police and doctors investigate
Shefali Jariwala was rushed to Bellevue Multispeciality Hospital by her husband and friends after she suddenly collapsed at home, but she was already unresponsive. Her family said she had been fasting for a religious ritual and had consumed her regular supplements shortly after breaking the fast. Among the substances recovered at her Andheri apartment were glutathione injections, commonly used for skin lightening, and various anti-ageing tablets.
Doctors at Cooper Hospital, where her post-mortem was conducted, suspect a fatal drop in blood pressure, though only the final autopsy will confirm the precise cause of death. So far, Mumbai Police have ruled out foul play and registered an accidental death report.
Health experts warn against unmonitored anti-ageing therapies
Experts are now urging caution over the growing trend of unsupervised beauty and anti-ageing regimens, especially among public figures. Dr Dhirendra Singhania, a leading cardiologist, pointed to steroids, hormone therapies, and poor sleep as major heart risk factors, even among seemingly fit individuals. While glutathione and vitamin C aren’t inherently dangerous, he said their misuse or interaction with other drugs can trigger complications.
Anti ageing pills found at Shefali Jariwala home spark health safety debate Instagram/shefalijariwala
Shefali had no known chronic illnesses apart from epilepsy, which doctors say is unlikely to be linked to her sudden collapse. Her death, while still under investigation, adds to growing concerns about beauty pressures, self-prescribed treatments, and the long-term risks of trying to defy ageing without medical oversight.
Keep ReadingShow less
Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear
• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy • Indian artisans and officials accused the brand of cultural appropriation • The footwear resembles traditional Kolhapuri chappals with GI status • Prada says designs are still in development and open to dialogue with India
Italian fashion label Prada has officially acknowledged that its Spring/Summer 2026 menswear collection includes footwear inspired by India’s traditional Kolhapuri chappals. The statement came after mounting criticism from Indian artisans and industry leaders, who claimed the brand showcased the design at Milan Fashion Week without recognising its origins.
Prada confirms Kolhapuri chappals inspired its 2026 Milan collectionInstagram/prada
Prada responds to Kolhapuri chappal row
In a letter addressed to Lalit Gandhi, President of the Maharashtra Chamber of Commerce, Industry and Agriculture (MACCIA), Prada’s CSR head Lorenzo Bertelli confirmed the sandals were influenced by Indian craftsmanship. The fashion house admitted that the open-toe leather sandals presented on the Milan runway drew from the centuries-old Kolhapuri style, traditionally made by artisans in Maharashtra and Karnataka.
Kolhapuri chappals have been crafted for centuries and received GI tag in 2019 iStock
The controversy erupted after Prada described the footwear simply as “leather sandals” in its show notes, omitting any reference to India. This led to accusations of cultural appropriation and disregard for artisans' rights. BJP MP Dhananjay Mahadik also led a group of Kolhapuri chappal makers to meet Maharashtra Chief Minister Devendra Fadnavis, urging government action to protect their Geographical Indication (GI) status.
No production yet, says Prada, as India seeks fair credit
Prada clarified that the sandals shown were part of an early-stage design process and have not been confirmed for mass production. “None of the pieces are finalised or approved for commercial use,” Bertelli wrote.
MACCIA, in its communication, called for proper acknowledgement and possible collaboration or compensation for Indian artisans. The organisation stressed that Kolhapuri chappals are not just heritage products but also vital to the livelihoods of thousands of families.
In response, Bertelli assured Prada’s commitment to ethical design, cultural respect, and further engagement with Indian artisan communities. He also welcomed the opportunity for open dialogue on potential partnerships.
The Kolhapuri chappal, awarded GI status in 2019, is a symbol of regional identity and craftsmanship. As global fashion continues to borrow from traditional cultures, this case may set the tone for how brands address ownership, recognition, and respect.
Keep ReadingShow less
Wintour’s style of leadership earned her the nickname “Nuclear Wintour”
Anna Wintour steps down as editor of US Vogue after 37 years
She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
Wintour transformed US Vogue into a global fashion authority
The 75-year-old has received numerous honours, including the Presidential Medal of Freedom
End of an era at US Vogue
Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.
The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.
A transformative legacy
Wintour took the helm of US Vogue in 1988, inheriting a relatively conservative magazine. She swiftly transformed it into a trendsetting, authoritative voice in fashion. Under her leadership, the publication became known for its iconic covers, high-end photography, and ability to shape careers in the fashion industry.
With extensive budgets and strong advertising support, Vogue became a global fashion flagship, influencing designers, celebrities, and brands worldwide.
Wintour’s style of leadership earned her the nickname “Nuclear Wintour” for her decisiveness, with some reports noting her tendency to make bold editorial decisions without extensive discussion. Her distinctive bob haircut and ever-present sunglasses made her a recognisable front-row figure at fashion weeks around the world.
Beyond the magazine
The British-born editor rose to wider public fame as the inspiration behind the character Miranda Priestly in The Devil Wears Prada — both the 2003 novel and the 2006 film adaptation. While Wintour rarely commented on the portrayal, she acknowledged the attention it brought, most recently during the launch of a stage musical adaptation in London in 2024.
She told the BBC, “They [my sunglasses] help me see and they help me not see. They help me be seen and not be seen. They are a prop, I would say.”
Wintour also became synonymous with the Met Gala, the annual high-profile charity event in New York City, which she has organised for years, drawing celebrities from fashion, film, politics, and sport.
Recognition and future plans
Wintour has received numerous accolades during her career. She was made a Dame Commander of the Order of the British Empire (DBE) in 2017 and became a Companion of Honour in February 2025. During the ceremony in London, she removed her sunglasses to receive the award and told King Charles III that she had no intention of retiring.
Wintour also became synonymous with the Met GalaGetty Images
In the United States, President Joe Biden awarded her the Presidential Medal of Freedom earlier this year before leaving office.
Despite stepping back from US Vogue, Wintour will continue to oversee several major Condé Nast titles including Wired, Vanity Fair, GQ, Condé Nast Traveler, and Glamour, as part of her global leadership responsibilities.
In her remarks to staff, she described the decision as “pivotal” but confirmed she would not be leaving the company or her office. “I’ll be turning all my attention to global leadership and working with our team of brilliant editors around the world,” she said.
Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
Health officials are investigating possible genetic causes behind the side-effects
Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
Adverse drug reactions cost the NHS an estimated £2.2bn annually
Health watchdog investigates spike in serious side-effects from GLP-1 drugs
UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.
The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.
What is acute pancreatitis?
Acute pancreatitis is a sudden inflammation of the pancreas, the gland located behind the stomach that helps with digestion. Symptoms typically include severe abdominal pain, nausea, and fever, and the condition often requires hospital treatment. In rare cases, it can be fatal.
Though pancreatitis is listed as an “uncommon” side-effect of GLP-1 medications in patient information leaflets – meaning it may affect around one in 100 people – the MHRA has seen a notable rise in reported incidents, particularly in 2025.
Since the start of the year, there have been 22 reports involving semaglutide (Ozempic and Wegovy) and 101 involving tirzepatide (Mounjaro).
Study launched to explore potential genetic link
To understand the possible causes of these side effects, particularly in light of rising usage of these medications, the MHRA is inviting affected patients to take part in a research study through the Yellow Card Biobank. The initiative, run by Genomics England, will collect saliva samples and other data to explore any genetic factors that may be influencing patient response to GLP-1 drugs.
An MHRA spokesperson stated: “Alongside increased usage, we are seeing an upturn in the number of Yellow Card reports mentioning GLP-1 medicines and acute pancreatitis.”
While no known genetic link has yet been established, the MHRA said genetic variations could help explain why some patients experience adverse reactions to certain medications. The agency is urging both patients and health professionals to report suspected side-effects related to these drugs.
Adverse reactions place burden on NHS
Research shows that one in six hospital admissions is caused by an adverse drug reaction, and around a third of those could potentially be avoided through genetic testing. The financial cost is also significant – the NHS spends over £2.2 billion each year on hospital stays linked to adverse reactions alone.
Dr Alison Cave, chief safety officer at the MHRA, highlighted the need for more personalised approaches to medicine: “Evidence shows that almost a third of side-effects to medicines could be prevented with the introduction of genetic testing.”
Manufacturers respond to rising concerns
In response to the reports, drugmakers Lilly and Novo Nordisk reiterated their commitment to patient safety and advised that side effects should always be reported and discussed with healthcare professionals.
A spokesperson for Lilly, which manufactures Mounjaro, said: “Patient safety is Lilly’s top priority. We take reports seriously and actively monitor, evaluate and report safety information for all our medicines.”
The Mounjaro leaflet identifies acute pancreatitis as an uncommon side-effect, advising patients to consult their doctor before using the drug if they have a history of the condition.
Novo Nordisk UK, which produces Ozempic and Wegovy, issued a similar statement: “Patient safety is of the utmost importance to Novo Nordisk… The known risks and benefits of GLP-1 medicines are described in the product information. We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional.”
Both companies said they were continuously collecting safety data and working with authorities to ensure ongoing monitoring and understanding of their treatments.
What should patients do?
Health officials are encouraging patients who have experienced severe symptoms such as abdominal pain, nausea, or fever after taking these medications to report their experiences to the Yellow Card scheme. Hospitalised individuals may be contacted to participate in the Biobank study.
While the overall safety profile of GLP-1 medicines remains positive, the MHRA has stressed the importance of vigilance as demand for these weight loss and diabetes drugs continues to grow.